MedTrace Logo

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

NCT02633033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2019-12-09

No results posted yet for this study

Summary

Acthar Gel was first approved by the Food and Drug Administration in 1952.

It has been used to treat many different illnesses, including multiple sclerosis.

This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS.

It will collect information on symptoms, recovery, treatment patterns and safety outcomes.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Sponsors & Collaborators

  • Mallinckrodt ARD Inc.

    collaborator UNKNOWN

  • Mallinckrodt

    lead INDUSTRY

Principal Investigators

  • Study Directo · Mallinckrodt

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-24
Primary Completion
2019-05-09
Completion
2019-05-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633033 on ClinicalTrials.gov